Patricia Cavazzoni, FDA's drug center director. The FDA announcement comes after the two leading monoclonal antibody treatments in the U.S. turned out to be ineffective against omicron....
The two medications had been the the backbone of antibody treatment, and doctors were hard pressed to come up with fallbacks when they didn’t work against omicron. Alternate therapies, including antiviral pills from Pfizer and Merck, have been in short supply....
The AP is solely responsible for all content.
综合
ABC新闻-商业新闻
2022-02-11 00:00:00.0